Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Elpiscience of Shanghai Raises $35 Million to Develop Immunotherapies

publication date: Dec 3, 2018

Elpiscience, a Shanghai immunoncology company, closed a $35 million Series B round led by Hillhouse Capital. Elpiscience has licensed technology from regional institutions and global partnerships to develop its pipeline, which now includes more than 10 molecules targeting novel pathways in cancer immunotherapy, including two assets that are ready for IND filing. In 2017, Elpiscience closed a $55 million Series A round that included Lilly Asia Ventures and CDH Investments. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020